Quarterly report pursuant to Section 13 or 15(d)

Significant Accounting Policies - Disaggregation of Revenue (Details)

v3.8.0.1
Significant Accounting Policies - Disaggregation of Revenue (Details) - USD ($)
3 Months Ended
Mar. 31, 2018
Mar. 31, 2017
Disaggregation of Revenue [Line Items]    
Total revenue $ 4,483 $ 384
Prescribed dietary supplements    
Disaggregation of Revenue [Line Items]    
Total revenue 2,231 0
Prescription drugs    
Disaggregation of Revenue [Line Items]    
Total revenue 2,029 0
Sales force revenue    
Disaggregation of Revenue [Line Items]    
Total revenue 223 0
Grant revenue    
Disaggregation of Revenue [Line Items]    
Total revenue $ 0 $ 384